Introduction. Hepatocellular carcinoma is one of the most prevalent cancers in the world and for less than 30-40% of patients radical treatment measures can be used. When such treatment options are not viable, systemic biological therapy with Sorafenib can be used. Sorafenib is a kinase inhibitor, that inhibits tumour cell proliferation and angiogenesis. The aim of this study is to determine treatment with Sorafenib efficacy depending on patients hepatic condition.
